Phase II Ramucirumab/Paclitaxel as Second-line Treatment in Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma With Integrative Genomic Analysis
Latest Information Update: 06 Nov 2021
Price :
$35 *
At a glance
- Drugs Paclitaxel (Primary) ; Ramucirumab (Primary)
- Indications Adenocarcinoma; Carcinoma; Gastric cancer; Oesophageal cancer
- Focus Therapeutic Use
- 17 Nov 2020 Status changed from active, no longer recruiting to completed.
- 03 Aug 2020 Planned primary completion date changed from 1 Jan 2020 to 1 Aug 2020.
- 03 Aug 2020 Status changed from recruiting to active, no longer recruiting.